An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib With Nivolumab in Patients With Unresectable or Metastatic Cancer
Latest Information Update: 16 Sep 2024
At a glance
- Drugs Nivolumab (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Alveolar soft part sarcoma; Gastric cancer; Haemangiosarcoma; Leiomyosarcoma; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Elevar Therapeutics
- 12 Sep 2024 Results presented in the Elevar Therapeutics Media Release.
- 12 Sep 2024 According to an Elevar Therapeutics media release, company will present data from this trial in a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, Sept. 13-17.
- 06 Apr 2023 Status changed from active, no longer recruiting to completed.